Detalles de la búsqueda
1.
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.
N Engl J Med
; 2024 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38767614
2.
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
N Engl J Med
; 389(3): 205-214, 2023 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37272521
3.
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.
N Engl J Med
; 387(25): 2317-2330, 2022 12 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36546624
4.
Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study.
Gut
; 73(3): 398-406, 2024 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38050037
5.
Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy.
Allergy
; 79(4): 894-907, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38279910
6.
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
J Am Acad Dermatol
; 90(6): 1190-1199, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38296199
7.
Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study.
Allergol Int
; 2024 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38735810
8.
The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases.
Allergol Int
; 67(3): 301-308, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29759659
9.
Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.
Ann Allergy Asthma Immunol
; 116(1): 59-65, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26553448
10.
Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
J Allergy Clin Immunol
; 135(6): 1494-501.e6, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25636947
11.
Short ragweeds is highly cross-reactive with other ragweeds.
Ann Allergy Asthma Immunol
; 115(6): 490-495.e1, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26507708
12.
Timothy specific IgE levels are associated with efficacy and safety of timothy grass sublingual immunotherapy tablet.
Ann Allergy Asthma Immunol
; 115(6): 509-515.e2, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26507709
13.
Safety and tolerability of a short ragweed sublingual immunotherapy tablet.
Ann Allergy Asthma Immunol
; 113(1): 93-100.e3, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24836393
14.
Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial.
Ann Allergy Asthma Immunol
; 112(2): 146-153.e2, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24468255
15.
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults.
J Allergy Clin Immunol
; 131(5): 1342-9.e6, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23622121
16.
Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT.
Adv Ther
; 2024 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38443648
17.
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study.
Lancet Respir Med
; 12(1): 45-54, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37956679
18.
Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults.
Ann Allergy Asthma Immunol
; 110(6): 450-456.e4, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23706715
19.
A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay.
J Allergy Clin Immunol
; 129(5): 1321-1328.e5, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22444503
20.
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Gastroenterol Hepatol
; 8(11): 990-1004, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37660704